Treating Lennox-Gastaut syndrome in epileptic pediatric patients with third-generation rufinamide.

Abstract

Lennox-Gastaut syndrome (LGS) is a rare but debilitating pediatric epileptic encephalopathy characterized by multiple intractable seizure types. Treatment of LGS is challenging because of the small number of antiepileptic drugs (AEDs) which are effective for this syndrome, as well as the need for polytherapy in the majority of patients. This review focuses on the treatment of LGS with rufinamide, a recently approved third-generation AED with reported efficacy as adjunctive therapy for LGS. All relevant papers identified through a PubMed search on the treatment of LGS with rufinamide were reviewed. To date, the literature suggests improvements in seizure frequency for pediatric patients with LGS on rufinamide. Rufinamide appears to be especially effective for atonic or drop attack seizures. Rufinamide also displays a favorable adverse event profile compared with the older anticonvulsants, as well as a minimal number of drug interactions, making it a promising option for the adjunctive treatment of seizures associated with LGS.

• Authors: Jessica Gresham, Lea S Eiland, Allison M Chung
• Journal: Neuropsychiatric disease and treatment (Neuropsychiatr Dis Treat) Vol. 6 Pg. 639-45 (Oct 05 2010) ISSN: 1178-2021 [Electronic] New Zealand
• PMID: 20957124 (Publication Type: Journal Article)